

Market Announcements Office
Australian Securities Exchange Limited
20 Bridge Street
SYDNEY NSW 2000

**Paradigm Biopharmaceuticals Limited (PAR) - Results of June 2026
General Meeting**

To: Australian Securities Exchange

In accordance with ASX Listing Rule 3.13.2 and Section 251AA of the Corporations Act 2001 (Cth), the attached information is provided in relation to the resolutions passed by the shareholders of Paradigm Biopharmaceuticals Limited at its General Meeting held on 11 June 2026.

Authorised for release by the Board of Directors.

Yours faithfully,

Abby Macnish Niven

Company Secretary & CFO

About Paradigm Biopharmaceuticals

Paradigm Biopharmaceuticals Ltd. (ASX: PAR) is a late-stage drug development company driven by a purpose to improve patients' health and quality of life by discovering, developing, and delivering pharmaceutical therapies. Paradigm's current focus is developing injectable pentosan polysulfate sodium (iPPS) for the treatment of diseases where inflammation plays a major pathogenic role, indicating a need for the anti-inflammatory and tissue regenerative properties of PPS, such as in osteoarthritis (phase 3).

To learn more please visit: <https://paradigmbiopharma.com>

FOR FURTHER INFORMATION PLEASE CONTACT:

Simon White

Director of Investor Relations

Tel: +61 404 216 467

Paradigm Biopharmaceuticals Ltd

ABN: 94 169 346 963

Level 15, 500 Collins St, Melbourne, VIC, 3000, AUSTRALIA

Email: investorrelations@paradigmbiopharma.com

Disclosure of Proxy Votes

Paradigm Biopharmaceuticals Limited

General Meeting

Thursday, 11 June 2026



Automic

GPO Box 5193, Sydney, NSW 2001

P 1300 288 664 (aus) or +61 (0)2 9698 5414 (world)

F +61 (0)2 8583 3040 E hello@automic.com.au

ABN 27 152 260 814

In accordance with section 251AA of the Corporations Act 2001, the following information is provided in relation to resolutions put to members at the meeting.

Resolution	Decided by Show of Hands (S) or Poll (P)	Total Number of Proxy Votes exercisable by proxies validly appointed	Proxy Votes				Poll Results (if applicable)			Results
			FOR	AGAINST	ABSTAIN	PROXY'S DISCRETION	FOR	AGAINST	ABSTAIN	OUTCOME
1 RATIFICATION OF PRIOR ISSUE OF PLACEMENT SHARES UNDER LISTING RULE 7.1	P	92,036,099	63,158,383 68.62%	28,616,004 31.09%	144,690	261,712 0.28%	66,726,588 69.99%	28,616,004 30.01%	144,690	Carried
2 RATIFICATION OF PRIOR ISSUE OF PLACEMENT SHARES UNDER LISTING RULE 7.1A	P	92,036,099	63,108,383 68.57%	28,668,204 31.15%	144,690	259,512 0.28%	66,674,388 69.93%	28,668,204 30.07%	144,690	Carried
3 APPROVAL TO ISSUE PLACEMENT OPTIONS	P	64,993,599	63,062,454 97.03%	1,673,633 2.58%	187,190	257,512 0.40%	66,436,583 97.27%	1,863,509 2.73%	187,190	Carried
4 APPROVAL TO ISSUE SPP OPTIONS	P	41,404,421	39,465,302 95.32%	1,681,607 4.06%	86,397	257,512 0.62%	42,318,080 95.76%	1,871,483 4.24%	86,397	Carried
5 APPROVAL TO ISSUE TRANCHE 4 CONVERTIBLE NOTES TO OBSIDIAN GLOBAL GP, LLC	P	114,315,934	83,014,968 72.62%	31,039,254 27.15%	155,733	261,712 0.23%	86,583,173 73.61%	31,039,254 26.39%	155,733	Carried

